Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Trastuzumab + Trebananib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Trastuzumab | Herceptin | Anti HER2 | HER2 (ERBB2) Antibody 58 | Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
Trebananib | AMG 386|AMG386 | Trebananib (AMG 386) inhibits angiogenesis through binding to the angiopoietins Ang1 and Ang2, thereby preventing interaction with their receptors (PMID: 32154928). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01042379 | Phase II | Trebananib Pertuzumab + Trastuzumab Ganitumab Cyclophosphamide + Doxorubicin + Paclitaxel MK2206 + Trastuzumab Trastuzumab + Trebananib Ado-trastuzumab emtansine + Pertuzumab | I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Recruiting | USA | 0 |